203 related articles for article (PubMed ID: 11770022)
1. Primary fibromatosis of the breast in a patient with multiple desmoid tumors--report of a case with evaluation of estrogen and progesterone receptors.
Reis-Filho JS; Milanezi F; Pope LZ; Fillus-Neto J; Schmitt FC
Pathol Res Pract; 2001; 197(11):775-9. PubMed ID: 11770022
[TBL] [Abstract][Full Text] [Related]
2. Prognostic factors in desmoid-type fibromatosis: a clinicopathological and immunohistochemical analysis of 46 cases.
Huang PW; Tzen CY
Pathology; 2010 Feb; 42(2):147-50. PubMed ID: 20085516
[TBL] [Abstract][Full Text] [Related]
3. Discordant expression of hormone receptors and HER2 in breast cancer. A retrospective comparison of primary tumors with paired metachronous recurrences or metastases.
Arapantoni-Dadioti P; Valavanis C; Gavressea T; Tzaida O; Trihia H; Lekka I
J BUON; 2012; 17(2):277-83. PubMed ID: 22740206
[TBL] [Abstract][Full Text] [Related]
4. WT1, estrogen receptor, and progesterone receptor as markers for breast or ovarian primary sites in metastatic adenocarcinoma to body fluids.
Lee BH; Hecht JL; Pinkus JL; Pinkus GS
Am J Clin Pathol; 2002 May; 117(5):745-50. PubMed ID: 12090423
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study.
Høgdall EV; Christensen L; Høgdall CK; Blaakaer J; Gayther S; Jacobs IJ; Christensen IJ; Kjaer SK
Oncol Rep; 2007 Nov; 18(5):1051-9. PubMed ID: 17914554
[TBL] [Abstract][Full Text] [Related]
6. [Clinicopathologic and genetic studies of desmoid-type fibromatosis].
Yang JL; Wang J; Zhou XY; Li XQ; Hou YY; Zhu XZ
Zhonghua Bing Li Xue Za Zhi; 2006 Mar; 35(3):145-50. PubMed ID: 16630502
[TBL] [Abstract][Full Text] [Related]
7. Bilateral breast fibromatosis: case report and review of the literature.
Taylor TV; Sosa J
J Surg Educ; 2011; 68(4):320-5. PubMed ID: 21708372
[TBL] [Abstract][Full Text] [Related]
8. An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.
Henriksen KL; Rasmussen BB; Lykkesfeldt AE; Møller S; Ejlertsen B; Mouridsen HT
Acta Oncol; 2009; 48(4):522-31. PubMed ID: 19173092
[TBL] [Abstract][Full Text] [Related]
9. Ratio of concentrations of estrogen receptors to progesterone receptors (ER/PR) in the cytosol of breast cancers (stratification by forming of groups differing in PR).
Hochmann J
Neoplasma; 2007; 54(4):290-6. PubMed ID: 17822318
[TBL] [Abstract][Full Text] [Related]
10. Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression.
Lindström LS; Karlsson E; Wilking UM; Johansson U; Hartman J; Lidbrink EK; Hatschek T; Skoog L; Bergh J
J Clin Oncol; 2012 Jul; 30(21):2601-8. PubMed ID: 22711854
[TBL] [Abstract][Full Text] [Related]
11. Impact of metastatic estrogen receptor and progesterone receptor status on survival.
Lower EE; Glass EL; Bradley DA; Blau R; Heffelfinger S
Breast Cancer Res Treat; 2005 Mar; 90(1):65-70. PubMed ID: 15770528
[TBL] [Abstract][Full Text] [Related]
12. Coordinated expression of ER, PR and HER2 define different prognostic subtypes among poorly differentiated breast carcinomas.
Fernandes RC; Bevilacqua JL; Soares IC; Siqueira SA; Pires L; Hegg R; Carvalho FM
Histopathology; 2009 Sep; 55(3):346-52. PubMed ID: 19723150
[TBL] [Abstract][Full Text] [Related]
13. Estrogen receptor-negative, progesterone receptor-positive breast carcinoma: poor clinical outcome.
Keshgegian AA; Cnaan A
Arch Pathol Lab Med; 1996 Oct; 120(10):970-3. PubMed ID: 12046611
[TBL] [Abstract][Full Text] [Related]
14. Fibromatosis of the male breast with concurrent florid-type gynecomastia: Report of a case and review of literature.
El Demellawy D; Herath C; Khalil M; Nasr A; Moussa B
Pathol Res Pract; 2011 May; 207(5):306-9. PubMed ID: 21511401
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical profile of the estrogen and progesterone receptors in mammary benign lesions.
Moise M; Răducan S; Boscu A; Jianu A; Niculescu M; Selaru M; Motoc A
Rev Med Chir Soc Med Nat Iasi; 2012; 116(3):875-82. PubMed ID: 23272545
[TBL] [Abstract][Full Text] [Related]
16. Bone metastasis is strongly associated with estrogen receptor-positive/progesterone receptor-negative breast carcinomas.
Wei B; Wang J; Bourne P; Yang Q; Hicks D; Bu H; Tang P
Hum Pathol; 2008 Dec; 39(12):1809-15. PubMed ID: 18715613
[TBL] [Abstract][Full Text] [Related]
17. Estrogen and progesterone hormone receptor status in breast carcinoma: comparison of immunocytochemistry and immunohistochemistry.
Radhika K; Prayaga AK
Indian J Cancer; 2010; 47(2):148-50. PubMed ID: 20448377
[TBL] [Abstract][Full Text] [Related]
18. [Desmoid tumor of the breast in a 9 years old little girl].
Muller M; Dessogne P; Baron M; Picquenot JM; Riopel C; Diologent B; Dupre PF; Collet M
Ann Pathol; 2011 Feb; 31(1):41-5. PubMed ID: 21349388
[TBL] [Abstract][Full Text] [Related]
19. Short-term outcome of primary operated early breast cancer by hormone and HER-2 receptors.
Brouckaert O; Pintens S; Van Belle V; Van Huffel S; Camerlynck E; Amant F; Leunen K; Smeets A; Berteloot P; Van Limbergen E; Decock J; Hendrickx W; Weltens C; Van den Bogaert W; Vanden Bempt I; Drijkoningen M; Paridaens R; Wildiers H; Vergote I; Christiaens MR; Neven P
Breast Cancer Res Treat; 2009 May; 115(2):349-58. PubMed ID: 18629635
[TBL] [Abstract][Full Text] [Related]
20. Giant recurrent fibromatosis of the breast: a case report. Clinical features and implications for treatment.
Catalano F; Furci M; Fancello R; Costanzo M
Chir Ital; 2006; 58(4):538-43. PubMed ID: 16999161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
